Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Clinical trial NCT04548791 · TERMINATED

Trial details

NCT number: NCT04548791
Sponsor: Catalyst Biosciences
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Factor VII Deficiency Glanzmann Thrombasthenia Hemophilia A With Inhibitor

Start date: 2021-05-17
Primary completion: 2021-11-15
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.